TCGA-BH-A0DQ-01A-11R-A084-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 3
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- TGF_BETA_SIGNALING+0.480
- COAGULATION+0.410
- MYOGENESIS+0.410
- ESTROGEN_RESPONSE_EARLY+0.360
- ESTROGEN_RESPONSE_LATE+0.360
- PANCREAS_BETA_CELLS+0.310
- COMPLEMENT+0.300
- APICAL_JUNCTION+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- MYC_TARGETS_V1-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.280
- E2F_TARGETS-0.270
- MTORC1_SIGNALING-0.250
- ALLOGRAFT_REJECTION-0.240
- OXIDATIVE_PHOSPHORYLATION-0.220
- G2M_CHECKPOINT-0.180
- CHOLESTEROL_HOMEOSTASIS-0.130
- GLYCOLYSIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208943 | — | — | 0.820 |
| 2 | SRR8518128 | — | A | 0.813 |
| 3 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.781 |
| 4 | SRR8942951 | — | — | 0.774 |
| 5 | MNG306 | — | — | 0.766 |
| 6 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.764 |
| 7 | SRR27320696 | — | — | 0.761 |
| 8 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.760 |
| 9 | SRR8518203 | — | A | 0.759 |
| 10 | SRR5088898 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |